Over One Million Prescriptions: How Australia Built a Major Medical Cannabis Market
Published February 1, 2022 — By Ann Karim, Senior Cannabis Editor
- Australia exceeded 1 million medical cannabis prescription approvals by 2022, with rapid month-on-month growth.
- Over 130 TGA-approved cannabis products were available to Australian prescribers by early 2022.
- Australia’s medical cannabis market reached an estimated A$500 million, making it Asia-Pacific’s fastest-growing cannabis market.
- The TGA rescheduled low-dose CBD to allow over-the-counter pharmacy access without prescription in 2021.
- Doctors can prescribe cannabis for a wide range of conditions including chronic pain, anxiety, epilepsy, and palliative care.
- Australia is a major medical cannabis producer and exporter, supplying global medical cannabis markets including Germany.
How Australia Built Its Medical Cannabis Framework
Australia authorized medical cannabis in principle in 2016, but the practical framework for patient access evolved gradually over the following years as the TGA developed its approval pathways, licensed cultivators and manufacturers built supply chains, and prescribing doctors navigated the requirements for authorizing cannabis medicines for their patients. By 2022, the cumulative investment in building out this framework had produced one of the most sophisticated and accessible medical cannabis systems outside of North America.
The key mechanism that drove Australia’s medical cannabis prescribing surge was the TGA’s Special Access Scheme and, more significantly, the Authorised Prescriber pathway that allowed doctors who established ongoing authority to prescribe cannabis for specific conditions to do so for subsequent patients without a per-patient TGA application. This streamlining was transformative: it reduced the administrative burden on prescribers from a multi-step application process for every patient to a credential that allowed ongoing prescribing once established. The result was a substantial increase in the number of doctors prescribing cannabis and a corresponding acceleration in prescription volumes from 2020 onward.
The breadth of conditions for which Australian doctors could prescribe cannabis was also notably permissive compared to European medical frameworks. While countries like France restricted its pilot program to five specific conditions, Australian prescribers could consider cannabis for chronic pain, anxiety, insomnia, PTSD, chemotherapy-induced nausea, epilepsy, multiple sclerosis spasticity, and palliative care — among many others — based on their clinical assessment of individual patient needs. This clinical flexibility reflected a regulatory philosophy that trusted doctor judgment rather than requiring condition-specific authorization for each therapeutic application.
“Australia has quietly built one of the world’s most accessible and sophisticated medical cannabis frameworks. The prescribing numbers are a reflection of genuine patient demand for a medicine that works for conditions where other options have failed.”
Over-the-Counter CBD: A 2021 Policy Shift
A policy change in February 2021 added another dimension to Australia’s cannabis accessibility story. The TGA rescheduled low-dose CBD products from Schedule 4 (prescription-only) to Schedule 3 (pharmacist-only, without prescription), allowing Australians to access CBD products meeting specific dosage criteria directly from pharmacies without seeing a doctor. This was a significant step that placed Australia ahead of most European countries in CBD access, while maintaining appropriate quality controls through the pharmacy distribution channel.
The over-the-counter CBD pathway was positioned as serving wellness and mild therapeutic applications — lower doses for conditions like mild anxiety or sleep support — while leaving higher-dose CBD and any THC-containing products in the prescription framework. The distinction was clinically defensible and regulatory prudent, addressing the consumer demand for accessible CBD wellness products without creating a fully unregulated market. Australians with more serious conditions requiring higher doses or THC-containing formulations continued to require prescriptions through the established medical cannabis framework.
Australia as a Medical Cannabis Exporter
Australia’s medical cannabis story is not just a domestic consumption story — it is also an export story. Australian licensed cultivators and manufacturers, operating under strict TGA-regulated Good Manufacturing Practice (GMP) standards, have developed significant export capacity. Australia became a supplier of medical cannabis flower, oil, and extracted products to Germany, the United Kingdom, and other markets with medical cannabis programs that had patient demand exceeding domestic licensed production capacity.
The export market was strategically significant for Australian cannabis companies, allowing them to diversify revenue beyond the domestic market and establish positions in European medical cannabis markets before those markets fully developed domestic supply chains. The Australian government recognized the export potential and developed regulatory pathways to facilitate compliant export of medical cannabis products, positioning the country as a high-quality, GMP-certified supplier in the global medical cannabis trade.
What Comes Next: Recreational Discussion Begins
While Australia’s medical cannabis revolution was firmly established by 2022, the question of recreational cannabis legalization was beginning to enter mainstream political discussion for the first time. Several Australian Capital Territory (ACT) residents were already operating under a regional decriminalization scheme. Australian Greens party members and some Labor party members had begun advocating for a national conversation about adult-use legalization. The success of the medical cannabis program in demonstrating that regulated cannabis could coexist with existing healthcare and safety frameworks provided advocates with empirical evidence for the feasibility of regulated recreational cannabis access in the Australian context.